SCHEMBL9893871

SCHEMBL9893871

Cc1cccc(-c2nc(C(=O)O)c(-c3cc(Cl)ccc3O)n2-c2cc(Cl)ccc2C)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 5/20 0.77
MAPT P10636 4/20 0.43
THRB P10828 3/20 0.43
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PIN1 Q13526 2/20 0.39
ATM Q13315 1/20 0.39
EGFR P00533 1/20 0.38
ALDH1A1 P00352 1/20 0.38
VEGFA P15692 1/20 0.37
FLT1 P17948 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1437312 0.94 MDM2 (0.74) MDM2MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL9893945 0.91 MDM2 (0.79) MDM2MAPTTHRBSMN1; SMN2HTT
SCHEMBL9894146 0.91 MDM2 (0.63) MDM2MAPTTHRBMEN1KMT2A
SCHEMBL9893927 0.87 MDM2 (1.00) MDM2MAPTTHRBSMN1; SMN2KDM4E
SCHEMBL9894203 0.87 MDM2 (0.73) MDM2MAPTTHRBSMN1; SMN2LMNA
SCHEMBL27862807 0.85 MDM2 (0.62) MDM2MAPTMEN1KMT2ANPC1
SCHEMBL9893657 0.85 MDM2 (0.73) MDM2MAPTTHRBSMN1; SMN2PIN1
SCHEMBL1437248 0.85 MDM2 (0.59) MDM2MAPTMEN1KMT2ANPC1
SCHEMBL9893637 0.84 MDM2 (0.84) MDM2MAPTSMN1; SMN2HTTPIN1
SCHEMBL9894206 0.83 MDM2 (0.83) MDM2MAPTSMN1; SMN2PIN1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885MAPT 582/4885THRB 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.